{"nctId":"NCT03611582","briefTitle":"Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program","startDateStruct":{"date":"2018-08-01","type":"ACTUAL"},"conditions":["Overweight","Obesity"],"count":611,"armGroups":[{"label":"Semaglutide","type":"EXPERIMENTAL","interventionNames":["Drug: Semaglutide"]},{"label":"Semaglutide placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo (semaglutide)"]}],"interventions":[{"name":"Semaglutide","otherNames":[]},{"name":"Placebo (semaglutide)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female, age more than or equal to 18 years at the time of signing informed consent\n* Body mass index more than or equal to 30 kg/m\\^2 or more than or equal to 27 kg/m\\^2 with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease\n* History of at least one self-reported unsuccessful dietary effort to lose body weight\n\nExclusion Criteria:\n\n* Hemoglobin A1c more than or equal to 48 mmol/mol (6.5%) as measured by the central laboratory at screening\n* A self-reported change in body weight more than 5 kg (11 lbs) within 90 days before screening irrespective of medical records","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Body Weight (%)","description":"Change in body weight from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from both in-trial and on-treatment periods. In-trial observation period: the uninterrupted time interval from the start of randomisation (week 0) to last trial-related subject-site contact (week 75). On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68), including 2 weeks of follow-up. It excludes any period of temporary treatment interruption. Temporary treatment interruption is defined as more than 2 consecutive missed doses (off-treatment period).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.5","spread":"10.1"},{"groupId":"OG001","value":"-5.8","spread":"7.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.6","spread":"9.6"},{"groupId":"OG001","value":"-6.1","spread":"7.6"}]}]}]},{"type":"PRIMARY","title":"Participants Who Achieve (Yes/no): Body Weight Reduction More Than or Equal to 5%","description":"Number of participants who achieved greater than or equal to (≥) 5% weight loss after 68 weeks is presented. In the reported data, 'Yes' infers the number of participants who have achieved ≥ 5% weight loss, whereas 'No' infers the number of participants who have not achieved ≥ 5% weight loss. The endpoint was evaluated based on the data from both in-trial and on-treatment observation periods. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75). On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68), including 2 weeks of follow-up. It excludes any period of temporary treatment interruption.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"323","spread":null},{"groupId":"OG001","value":"90","spread":null}]},{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"300","spread":null},{"groupId":"OG001","value":"82","spread":null}]},{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"82","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants Who Achieve (Yes/no): Body Weight Reduction More Than or Equal to 10%","description":"Number of participants who achieved greater than or equal to (≥) 10% weight loss after 68 weeks is presented. In the reported data, 'Yes' infers number of participants who have achieved ≥ 10% weight loss whereas 'No' infers number of participants who have not achieved ≥ 10% weight loss. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"281","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"138","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants Who Achieve (Yes/no): Body Weight Reduction More Than or Equal to 15%","description":"Number of participants who achieved greater than or equal to (≥) 15% weight loss after 68 weeks is presented. In the reported data, 'Yes' infers number of participants who have achieved ≥ 15% weight loss whereas 'No' infers number of participants who have not achieved ≥ 15% weight loss. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"208","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"165","spread":null},{"groupId":"OG001","value":"164","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants Who Achieve (Yes/no): Body Weight Reduction More Than or Equal to 20%","description":"Number of participants who achieved greater than or equal to (≥) 20% weight loss after 68 weeks is presented. In the reported data, 'Yes' infers number of participants who have achieved ≥ 20% weight loss whereas 'No' infers number of participants who have not achieved ≥ 20% weight loss. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"133","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"240","spread":null},{"groupId":"OG001","value":"182","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Waist Circumference","description":"Change in waist circumference from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.2","spread":"10.2"},{"groupId":"OG001","value":"-6.1","spread":"8.6"}]}]}]},{"type":"SECONDARY","title":"Change in Systolic Blood Pressure","description":"Change in systolic blood pressure from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6","spread":"14"},{"groupId":"OG001","value":"-2","spread":"15"}]}]}]},{"type":"SECONDARY","title":"Change in Short Form-36 (SF-36) - Physical Functioning Score","description":"SF-36 is a 36-item patient-reported survey of patient health that measures the participant's overall health-related quality of life (HRQoL). SF-36v2™ questionnaire measured eight domains of functional health and well-being as well as two component summary scores (physical component summary and mental component summary). The 0-100 scale scores from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. In the metric of norm-based scores, 50 and 10 corresponds to the mean and standard deviation respectively. Change from week 0 in the domain scores and component summary scores were evaluated at week 68. A positive change score indicates an improvement since baseline. These endpoints were evaluated based on the data from in-trial observation period which is the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"5.7"},{"groupId":"OG001","value":"1.7","spread":"5.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"6.5"},{"groupId":"OG001","value":"1.5","spread":"6.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"7.1"},{"groupId":"OG001","value":"0.6","spread":"8.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"6.6"},{"groupId":"OG001","value":"1.9","spread":"6.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"8.2"},{"groupId":"OG001","value":"0.9","spread":"7.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"6.6"},{"groupId":"OG001","value":"-1.2","spread":"8.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"6.0"},{"groupId":"OG001","value":"-1.5","spread":"7.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"6.0"},{"groupId":"OG001","value":"2.6","spread":"6.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"6.0"},{"groupId":"OG001","value":"-2.2","spread":"8.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"5.6"},{"groupId":"OG001","value":"-1.5","spread":"7.7"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight (Kg)","description":"Change in body weight from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.5","spread":"11.4"},{"groupId":"OG001","value":"-6.2","spread":"8.6"}]}]}]},{"type":"SECONDARY","title":"Change in Body Mass Index","description":"Change in body mass index from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.2","spread":"4.0"},{"groupId":"OG001","value":"-2.2","spread":"3.1"}]}]}]},{"type":"SECONDARY","title":"Change in HbA1c (%)","description":"Change in glycosylated haemoglobin (HbA1c) from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.3"},{"groupId":"OG001","value":"-0.3","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Change in HbA1c (mmol/Mol)","description":"Change in HbA1c from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.8","spread":"3.1"},{"groupId":"OG001","value":"-3.1","spread":"2.5"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose","description":"Change in fasting plasma glucose from week 0 to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.3","spread":"10.9"},{"groupId":"OG001","value":"-1.1","spread":"10.6"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Serum Insulin","description":"Change in fasting serum insulin from week 0 to week 68 \\[measured as milli-international units per milliliter (mIU/mL)\\] is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.68","spread":"67.4"},{"groupId":"OG001","value":"0.84","spread":"50.6"}]}]}]},{"type":"SECONDARY","title":"Change in Diastolic Blood Pressure","description":"Change in diastolic blood pressure from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3","spread":"10"},{"groupId":"OG001","value":"-1","spread":"10"}]}]}]},{"type":"SECONDARY","title":"Change in Total Cholesterol","description":"Change in fasting total cholesterol from baseline (week 0) to week 68 (measured as mg/dL) is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.96","spread":"15.0"},{"groupId":"OG001","value":"1.01","spread":"12.3"}]}]}]},{"type":"SECONDARY","title":"Change in High-density Lipoproteins (HDL)","description":"Change in fasting HDL from baseline (week 0) to week 68 (measured as mg/dL) is presented as ratio to baseline.The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.06","spread":"14.6"},{"groupId":"OG001","value":"1.05","spread":"15.0"}]}]}]},{"type":"SECONDARY","title":"Change in Low-density Lipoproteins (LDL)","description":"Change in fasting LDL from baseline (week 0) to week 68 (measured as mg/dL) is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.96","spread":"23.2"},{"groupId":"OG001","value":"1.01","spread":"18.6"}]}]}]},{"type":"SECONDARY","title":"Change in Very Low Density Lipoprotein (VLDL)","description":"Change in fasting VLDL from baseline (week 0) to week 68 (measured as mg/dL) is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.77","spread":"40.9"},{"groupId":"OG001","value":"0.91","spread":"38.6"}]}]}]},{"type":"SECONDARY","title":"Change in Free Fatty Acids","description":"Change in fasting free fatty acids from baseline (week 0) to week 68 (measured as mg/dL) is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.86","spread":"69.9"},{"groupId":"OG001","value":"1.08","spread":"71.8"}]}]}]},{"type":"SECONDARY","title":"Change in Triglycerides","description":"Change in fasting triglycerides from baseline (week 0) to week 68 (measured as mg/dL) is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.77","spread":"41.3"},{"groupId":"OG001","value":"0.91","spread":"39.1"}]}]}]},{"type":"SECONDARY","title":"Change in High Sensitivity C-reactive Protein","description":"Change in high sensitivity C-reactive protein from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.40","spread":"108.7"},{"groupId":"OG001","value":"0.76","spread":"75.5"}]}]}]},{"type":"SECONDARY","title":"Change in Plasminogen Activator Inhibitor-1 Activity","description":"Change in plasminogen activator inhibitor-1 activity from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.92","spread":"80.6"},{"groupId":"OG001","value":"1.26","spread":"74.2"}]}]}]},{"type":"SECONDARY","title":"Participants Who Achieve (Yes/no): Responder Definition Value for SF-36 Physical Functioning Score","description":"The observed number of participants experiencing a meaningful within participant improvement in SF-36 Physical function after 68 weeks was determined based on two thresholds. The threshold of 4.3 is the default generic responder threshold defined in SF-36 manual for a general population. The threshold of 3.7 is specific for overweight or obese population included in the study and calculated using patient global rating anchor questionnaires to reflect participants' own perspective based on Food and Drug Administration (FDA) recommendations. In the reported data, \"Yes\" infers number of participants who have achieved an improvement in score greater than or equal to the threshold and \"No\" infers number of participants who have not achieved an improvement in score greater than or equal to the threshold. The endpoint was evaluated based on the in-trial observation period which is uninterrupted time interval from randomization (week 0) to last trial related subject-site contact (week 75).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"278","spread":null},{"groupId":"OG001","value":"145","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"133","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"231","spread":null},{"groupId":"OG001","value":"130","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight","description":"Change in body weight from baseline (week 0) to week 8 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.8","spread":"3.1"},{"groupId":"OG001","value":"-6.0","spread":"3.6"}]}]}]},{"type":"SECONDARY","title":"Number of Treatment-emergent Adverse Events (AEs)","description":"An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. All AEs mentioned here are treatment emergent adverse events (TEAE) defined as an event that had onset date (or increase in severity) on or after the first day of exposure to treatment. The endpoint was evaluated based on the data from on-treatment observation period. On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68), including 7 weeks of follow-up. It excludes any period of temporary treatment interruption. Temporary treatment interruption is defined as more than 7 consecutive missed doses (off-treatment period).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4035","spread":null},{"groupId":"OG001","value":"1325","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Serious Adverse Events (SAEs)","description":"A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose results in death, or is life-threatening, or requires inpatient hospitalization or causes prolongation of existing hospitalization results in persistent or significant disability/incapacity, or may have caused a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage. The SAEs occurred from week 0 to week 75 is presented. The endpoint was evaluated based on the data from on-treatment observation period. On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68), including 7 weeks of follow-up. It excludes any period of temporary treatment interruption. Temporary treatment interruption is defined as more than 7 consecutive missed doses (off-treatment period).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Pulse","description":"Change in pulse from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from on-treatment observation period. On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68) including 2 weeks of follow-up. It excludes any period of temporary treatment interruption. Temporary treatment interruption is defined as more than 2 consecutive missed doses (off-treatment period).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":"11"},{"groupId":"OG001","value":"2","spread":"10"}]}]}]},{"type":"SECONDARY","title":"Change in Amylase","description":"Change in amylase (measured as U/L) is presented as ratio to baseline. The endpoint was evaluated based on the data from on-treatment observation period. On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68) including 2 weeks of follow-up. It excludes any period of temporary treatment interruption. Temporary treatment interruption is defined as more than 2 consecutive missed doses (off-treatment period).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.12","spread":"19"},{"groupId":"OG001","value":"1.07","spread":"18.1"}]}]}]},{"type":"SECONDARY","title":"Change in Lipase","description":"Change in lipase (measured as U/L) is presented as ratio to baseline. The endpoint was evaluated based on the data from on-treatment observation period. On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68) including 2 weeks of follow-up. It excludes any period of temporary treatment interruption. Temporary treatment interruption is defined as more than 2 consecutive missed doses (off-treatment period).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.31","spread":"52"},{"groupId":"OG001","value":"0.94","spread":"39.4"}]}]}]},{"type":"SECONDARY","title":"Change in Calcitonin","description":"Change in calcitonin (measured as ng/L) is presented as ratio to baseline. The endpoint was evaluated based on the data from on-treatment observation period. On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68) including 2 weeks of follow-up. It excludes any period of temporary treatment interruption. Temporary treatment interruption is defined as more than 2 consecutive missed doses (off-treatment period).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.93","spread":"40.6"},{"groupId":"OG001","value":"0.94","spread":"33.2"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":37,"n":407},"commonTop":["Nausea","Constipation","Diarrhoea","Nasopharyngitis","Vomiting"]}}}